CHRISTIN L. HERTZ

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial”.

Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial

BMJ Open Diabetes Research & Care(2020)10.1136/bmjdrc-2020-001649

N/A

1.6DataRank · unranked

36 citations

Bruce W. Bode, Ann Mertens, Young Min Cho, Erik Christiansen, CHRISTIN L. HERTZ +3 more

Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses

Diabetes Therapy(2021)10.1007/s13300-020-00994-9

N/A

0.968DataRank · unranked

20 citations

Matthew J. Crowley, Mette Gislum, CHRISTIN L. HERTZ, Thomas Bo Jensen, Kamlesh Khunti +3 more